RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference ...

After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), ...

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares are trading higher Monday after the company announced it entered into a ...

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), has entered into a distribution services agreement with Cardinal Health (CAH).

Citius Pharmaceuticals Inc (NASDAQ: CTXR ), the parent company of Citius Oncology, also saw its shares climb by 6.7%. Meanwhile, Cardinal Health’s stock remained flat after the news.

BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that its poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting has received ...

Today marks a transformative moment in the 35-year history of the American Sleep Apnea Association (ASAA). The organization proudly rebrands as the Wellness, Sleep & Circadian Network (WSCN), a global ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.